Details

Autor(en) / Beteiligte

• PUSZTAI, L
• HOLMES, F. A
• FRASCHINI, G
• HORTOBAGYI, G. N

Titel

Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy

Ist Teil von

• Cancer chemotherapy and pharmacology, 1999, Vol.43 (1), p.86-91

Ort / Verlag

Berlin: Springer

Erscheinungsjahr

1999

Link zum Volltext

Quelle

SpringerLINK Contemporary (Konsortium Baden-Württemberg)

Beschreibungen/Notizen

• Early phase II evaluation of intravenous bolus mitoxantrone indicated objective response rates of 17 36% in patients with metastatic breast cancer. Subsequently, it has been suggested that continuous infusion may be the optimal way to administer this drug in order to achieve maximal cytotoxic effect with minimal toxicity. We present the results of a phase II study that evaluated the efficacy and side effects of mitoxantrone administered at the maximally tolerated dose by continuous infusion in patients with metastatic breast cancer. This study included 16 patients with metastatic breast cancer and limited previous therapy for their metastatic disease. Mitoxantrone, 1.5 mg/m2 per day, was given by continuous intravenous infusion for 14 consecutive days repeated every 21 days with concomitant granulocyte colony-stimulating factor support. Dose escalation was allowed. No complete tumor response was seen. Two patients (13%, CI 0-29%) had a partial response, nine patients (56%) had progressive disease and the remaining five patients (31%) had stable disease on therapy. The major dose-limiting side effect was myelotoxicity. Two of the 16 patients (13%) experienced asymptomatic cardiotoxicity that required discontinuation of therapy. Our results indicate limited antitumor activity and significant toxicity of mitoxantrone given by continuous infusion as second-line chemotherapy for metastatic breast cancer. The objective response rate documented in this study is inferior to response rates reported with other second-line regimens, particularly the taxanes, now available for this patient population.